Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AQUAPHYLLIN vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Maintenance treatment of asthma,Chronic obstructive pulmonary disease (COPD) exacerbations
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4 and CYP2E1.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 85-95%; intramuscular: 75-90%.
Oral: 40-50%; Inhalation: 20-30%
No adjustment required.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
In Child-Pugh Class B or C, reduce dose by 50% and monitor serum theophylline levels.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Loading dose: 5 mg/kg orally. Maintenance: 4 mg/kg orally every 6 hours for children 1-9 years; 3 mg/kg orally every 6 hours for children 10-16 years. Maximum daily dose: 24 mg/kg.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Use lower initial dose (e.g., 200 mg orally every 8 hours) and titrate slowly; monitor serum theophylline levels due to decreased clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None
No FDA black box warning.
Cardiovascular events: arrhythmias, tachycardia, hypotension,Seizures in patients with history of seizure disorder,Significant drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin),Overdose risk: narrow therapeutic index, monitor serum levels
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or other xanthines,Active seizure disorders (relative),Uncontrolled cardiac arrhythmias
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase theophylline levels and risk of toxicity. High-protein, low-carbohydrate diets may decrease theophylline metabolism; low-protein, high-carbohydrate diets may increase metabolism. Consistent dietary habits are recommended. Charcoal-broiled meats may increase metabolism.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea, tachycardia, and jitteriness due to transplacental passage. Maternal toxicity at high doses may cause fetal hypoxia.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted in breast milk with M/P ratio approximately 0.6-0.7. Infant plasma levels may reach 10-50% of maternal levels. Monitor infant for irritability, insomnia, and feeding difficulties. Use caution and consider alternative agents if infant is premature or has cardiovascular disease.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy increases theophylline clearance by 30-50% due to increased hepatic metabolism and renal perfusion. Dose may need to be increased by 30% to maintain therapeutic levels (5-15 mcg/m L). Monitor serum levels frequently and adjust accordingly.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Aquaphyllin (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L for optimal bronchodilation. Monitor for toxicity (nausea, vomiting, tremor, tachycardia) especially in patients with hepatic impairment, heart failure, or concurrent use of CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Smoking induces theophylline metabolism requiring higher doses. Use with caution in elderly and patients with seizure disorders.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine-containing foods or beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity such as persistent nausea, vomiting, rapid or irregular heartbeat, or seizures immediately.,Do not stop taking this medication abruptly; taper under medical supervision.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,If you smoke, tell your doctor; changes in smoking habits may require dose adjustment.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AQUAPHYLLIN vs AEROLATE III, answered by our medical review team.
AQUAPHYLLIN is a Bronchodilator that works by Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AQUAPHYLLIN and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AQUAPHYLLIN is: 300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AQUAPHYLLIN and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AQUAPHYLLIN is classified as Category C. Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.